{Reference Type}: Case Reports
{Title}: Anti-interleukin-5 therapy (mepolizumab) in life-threatening asthma attack: A case-based discussion.
{Author}: Tello K;Hoffmann A;Beutel B;Greulich T;Vogelmeier CF;Richter MJ;Kuhnert S;Böselt T;Alter P;Holland A;Idzko M;Buhl R;Koczulla AR;
{Journal}: Respir Med Case Rep
{Volume}: 28
{Issue}: 0
{Year}: 2019
暂无{DOI}: 10.1016/j.rmcr.2019.100927
{Abstract}: We report about a case of a compassionate off-label use of the anti-interleukin-5-agent mepolizumab in a ventilated patient with life-threatening asthma attack in eosinophilic asthma. The patient suffered from severe eosinophilic asthma and was transmitted to our hospital with an asthma attack and a life-threatening respiratory state under ventilation. Since high dose steroids had not yielded a sufficient respiratory improvement mepolizumab was administered subcutaneously. After administration of mepolizumab respiratory state and ventilation parameter improved significantly. Two days after administration the patient was weaned could be extubated 8 days later and recovered completely from the asthma attack. The presented clinical case is suggestive of future clinical trials or registry studies to evaluate potential clinical benefits of anti-interleukin-5 treatment in patients with severe exacerbations of eosinophilic asthma.